Formulation: A crystalline solid
Formal Name: 3-[4-[2-butyl-1-[4-(4-chlorophenoxy)phenyl]-1H-imidazol-4-yl]phenoxy]-N,N-diethyl-1-propanamine
Purity: ≥98%
Formula Markup: C32H38ClN3O2
Formula Weight: 532,1
Shelf life (days): 1460
CAS Number: 603148-36-3
Notes: Azeliragon is an orally bioavailable inhibitor of the receptor for advanced glycation endproducts (RAGE; Kd = 12.7 nM for human recombinant sRAGE), which transports amyloid-β (Aβ) from plasma into the CNS.{39734} It is selective for sRAGE over greater than 100 receptors and transporters in a screening assay. Azeliragon (0.3, 1, and 3 mg/kg per day) prevents brain deposition of Aβ (1-40) (Aβ40) and Aβ42 in the APP/SWE/LON transgenic mouse model of Alzheimer’s disease and increases plasma Aβ levels when administered for three months starting at 12 months of age. In the same treatment paradigm, it dose-dependently reduces memory impairments in the Morris water maze compared with untreated control mice, decreasing the latency and distance traveled to the platform. Azeliragon (10 mg/kg) also increases cerebral blood flow in the hippocampus and frontal cortex in tgAPP/SWE/LON mice greater than six months old.
English
Deutsch
